Zydus settles patent case over Aptalis' drug Canasa

As a result of the settlement, the company's "US subsidiary, Zydus Pharmaceuticals (USA) Inc, will be able to market its generic version of Canasa in the United States beginning on June 13, 2019, or earlier under certain circumstances," Cadila Healthcare said in a statement.PTI | August 14, 2017, 18:01 IST

New Delhi: Zydus group firm Cadila Healthcare on Monday said patent litigation relating to Aptalis' drug Canasa used for treatment of ulcerative colitis has been settled.

As a result of the settlement, the company's "US subsidiary, Zydus Pharmaceuticals (USA) Inc, will be able to market its generic version of Canasa in the United States beginning on June 13, 2019, or earlier under certain circumstances," Cadila Healthcare said in a statement.

Zydus Cadila had earlier received tentative approval from the United States Food and Drug Administration (USFDA) to market its generic version of Canasa (mesalamine suppository 1 g), it added.